Mobile

Clinical research study involving an experimental combination medication called EVG/COBI/FTC/TDF. This is 1 pill containing 2 experimental medications, EVG and COBI, plus 2 medications already approve...

Mise à jour : Il y a 5 ans
Référence : EUCTR2012-003708-11

Clinical research study involving an experimental combination medication called EVG/COBI/FTC/TDF. This is 1 pill containing 2 experimental medications, EVG and COBI, plus 2 medications already approved for the treatment of HIV-1 infection, FTC and TDF. In this study neither the patient or the investigator will know whether the patient is receiving EVG/COBI/FTC/TDF or the comparator drug ritonavir-boosted atazanavir with FTC/TDF. This is a randomized (by chance, like a flip of a coin) study

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumarate in HIV-1 infected, antiretroviral treatment-naïve adult women as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 48

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infections

Liens